(Q38189135)

30 August 2017

title

Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? (English)

1 reference

30 August 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

George Anderson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Marta Kubera

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Michael Maes

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

English

0 references

publication date

19 February 2014

1 reference

Expert Opinion on Therapeutic Targets

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

495-512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24548241%20AND%20SRC:MED&resulttype=core&format=json

A review on the acute phase response in major depression

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

A meta-analysis of cytokines in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

CD4 T cells: fates, functions, and faults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6, a major cytokine in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6 and chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Immunoendocrine aspects of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Indicators of immune activation in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The role of immune genes in the association between depression and inflammation: a review of recent clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Overnight changes of immune parameters and catecholamines are associated with mood and stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Cytokine levels in the blood may distinguish suicide attempters from depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Lower CSF interleukin-6 predicts future depression in a population-based sample of older women followed for 17 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Proinflammatory and "resiliency" proteins in the CSF of patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Role of cytokines in atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Zinc in depression: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Alterations in iron metabolism and the erythron in major depression: Further evidence for a chronic inflammatory process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6 production and deregulation of the hypothalamic-pituitary-adrenal axis in patients with major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Serotonin-immune interactions in detoxified chronic alcoholic patients without apparent liver disease: activation of the inflammatory response system and lower plasma total tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Anti-IL-6 antibody treatment but not IL-6 knockout improves intestinal barrier function and reduces inflammation after binge ethanol exposure and burn injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Immune modulation of learning, memory, neural plasticity and neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The monocyte-T-lymphocyte hypothesis of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

So depression is an inflammatory disease, but where does the inflammation come from?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

21 January 2018

Brain IL-6 and autism

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Risk of postpartum depression in association with serum leptin and interleukin-6 levels at delivery: a nested case-control study within the UPPSAT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Psychological and behavioural effects of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Immune challenge induces differential corticosterone and interleukin-6 responsiveness in rats bred for extremes in anxiety-related behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

CD4+CD25+ regulatory T cell depletion modulates anxiety and depression-like behaviors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Constant darkness induces IL-6-dependent depression-like behavior through the NF-κB signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-2 and -6 induce behavioral-activating effects in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Behavioral effects of infection with IL-6 adenovector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

IL-6 mediated alterations on immobile behavior of rats in the forced swim test via ERK1/2 activation in specific brain regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

In vitro immunoregulatory effects of lithium in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

IL-6 levels decrease with SSRI treatment in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Association of depressive disorders, depression characteristics and antidepressant medication with inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Antidepressants and neuroinflammation: Can antidepressants calm glial rage down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Stimulatory effect of antidepressants on the production of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Phenelzine (monoamine oxidase inhibitor) increases production of nitric oxide and proinflammatory cytokines via the NF-κB pathway in lipopolysaccharide-activated microglia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Serotonin via 5-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

The effects of noradrenaline and alpha-2 adrenoceptor agents on the production of monocytic products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Dopamine agonists upregulate IL-6 and IL-8 production in human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Does dopamine dysfunction drive depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Passage of cytokines across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Cytokines as biomarkers in depressive disorder: current standing and prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Putative neuroprotective agents in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Biologic therapy for autoimmune diseases: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Hitting a complex target: an update on interleukin-6 trans-signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Targeting IL-1 in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417

Acute phase proteins in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.888417